Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Carcinoma 3 Fallopian Tube Neoplasms 2 Sarcoma 1 Renal Insufficiency 1 Melanoma 1 Leukemia, Myelomonocytic, Acute 1 Leukemia, Myeloid, Acute 1 Leukemia, Monocytic, Acute 1 Leukemia, Megakaryoblastic, Acute 1 Leukemia, Erythroblastic, Acute 1 Kidney Neoplasms 1 Kidney Diseases 1 Congenital Abnormalities 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Advanced Solid Tumors 1

Interventions

Doxorubicin 27 Cyclophosphamide 26 Radiotherapy 16 Gemcitabine 16 Filgrastim 11 pembrolizumab 10 pazopanib 10 Radiation 9 Docetaxel 9 Cisplatin 9 fludarabine 7 Trabectedin 7 Ipilimumab 7 Ifosfamide 7 Granulocyte Colony-Stimulating Factor 7 Etoposide 7 Carboplatin 7 Busulfan 7 Bevacizumab 7 olaratumab 6 Temozolomide 6 Peripheral Blood Stem Cell Transplantation 6 Nivolumab 6 Mesna 6 Melphalan 6 selinexor 5 Leucovorin 5 Irinotecan 5 Celecoxib 5 Bortezomib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Sarcoma × trebananib × Clear all

NCT01992341 2014-09-23

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Amgen

Phase 1 Completed

Carcinoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡